Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
$OKYO MomentumIts gaining last trade up | Pisd | investorshub | 09/25/2023 12:25:58 PM |
$OKYO must see | Sirpeter | investorshub | 09/25/2023 11:42:58 AM |
$OKYO The gaining up | glenn1919 | investorshub | 09/25/2023 11:14:33 AM |
Have a look at this | Count Crypto | investorshub | 09/25/2023 10:56:43 AM |
Price gaining | mfayman | investorshub | 09/25/2023 4:48:42 AM |
$OKYO MomentumIts gaining | Sirpeter | investorshub | 09/25/2023 3:01:21 AM |
$OKYO bulls and bears | Sirpeter | investorshub | 09/25/2023 1:55:13 AM |
Price trading | mfayman | investorshub | 09/25/2023 1:51:26 AM |
$OKYO MomentumIts now | mfayman | investorshub | 09/25/2023 1:33:10 AM |
must see | mfayman | investorshub | 09/25/2023 1:01:41 AM |
Price trading | Monksdream | investorshub | 09/25/2023 12:46:14 AM |
news out | mfayman | investorshub | 09/24/2023 10:32:53 PM |
$OKYO Have a look at this | oldstocks | investorshub | 09/24/2023 9:20:27 PM |
Looks pretty positive | StocksNcash | investorshub | 09/24/2023 8:15:56 PM |
is it bear time? Or do we go bull? | mfayman | investorshub | 09/24/2023 8:12:55 PM |
$OKYO MomentumIts trading | mfayman | investorshub | 09/24/2023 6:00:51 PM |
$OKYO and the shorts continue | mfayman | investorshub | 09/24/2023 5:42:55 PM |
$OKYO short squeeze signal | mfayman | investorshub | 09/24/2023 4:46:30 PM |
$OKYO we got news | Count Crypto | investorshub | 09/24/2023 2:59:15 PM |
$OKYO What do you make of this? | mfayman | investorshub | 09/24/2023 2:51:58 PM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...